Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
Open Access
- 13 October 2016
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 115 (11) , 1335-1342
Abstract
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.Keywords
This publication has 30 references indexed in Scilit:
- Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic reviewCancer Treatment Reviews, 2015
- Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with PaclitaxelClinical Cancer Research, 2014
- CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced NeurotoxicityClinical Cancer Research, 2013
- A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101Clinical Cancer Research, 2012
- Impact ofABCB1Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian CancerBasic & Clinical Pharmacology & Toxicology, 2011
- Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancerEuropean Journal of Clinical Pharmacology, 2011
- Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancerThe Pharmacogenomics Journal, 2010
- Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancerAnnals of Oncology, 2010
- Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian CancerBasic & Clinical Pharmacology & Toxicology, 2009
- CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomesBiochemical Pharmacology, 2002